Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

FMS US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

FMS US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Fresenius Medical Care AG American Depositary Receipt(FMS US)

$22.03+0.431.99%Ext:$23.17+1.145.16%(After Hours · 23:13:57 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Fresenius Medical Care AG American Depositary Receipt(FMS US)

$22.03+0.431.99%Ext:$23.17+1.145.16%(After Hours · 23:13:57 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Financials & Metrics

FinancialsChartingShort InterestEmployees

Fresenius Medical Care AG American Depositary Receipt — Company Profile

Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.

Sector
Healthcare
Industry
Medical - Care Facilities
Exchange
UN
CEO
Helen Giza
Headquarters
Bad Homburg, 2M, DE
IPO Date
Sep 17, 1996
Employees
108,165
Website
www.freseniusmedicalcare.com

Key Metrics

Price
$22.34
Market Cap
$12.00B
Revenue (TTM)
$4.61B
Net Income (TTM)
$117.53M
EPS (TTM)
0.22

Fresenius Medical Care AG American Depositary Receipt — Company Profile

Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.

Sector
Healthcare
Industry
Medical - Care Facilities
Exchange
UN
CEO
Helen Giza
Headquarters
Bad Homburg, 2M, DE
IPO Date
Sep 17, 1996
Employees
108,165
Website
www.freseniusmedicalcare.com

Key Metrics

Price
$22.34
Market Cap
$12.00B
Revenue (TTM)
$4.61B
Net Income (TTM)
$117.53M
EPS (TTM)
0.22
P/E (TTM)
12.71
P/B (TTM)
0.91
Dividend Yield
4.03%
ROE (TTM)
0.89%
ROA (TTM)
0.37%
Operating Margin
8.14%
Beta
0.37

Dividends

Last Dividend
$0.87
Last Yield
0.04%

Summary

Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.

Website
www.freseniusmedicalcare.com
Location
Bad Homburg, 2M, DE
Phone49 6172 608 2522
Employees108,165
CEOHelen Giza
SectorHealthcare
IndustryMedical - Care Facilities
IPO DateSep 17, 1996

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(572)

Expand
  • SC 13D/AFresenius Medical Care AG03:26PM
  • 6-KCurrent report (foreign private issuer)9 Nov
  • 6-KCurrent report (foreign private issuer)3 Nov
  • 6-KCurrent report (foreign private issuer)3 Nov
  • 6-KCurrent report (foreign private issuer)7 Oct
  • 6-KCurrent report (foreign private issuer)25 Sep
  • 6-KCurrent report (foreign private issuer)27 Aug
  • SC 13D/AFresenius Medical Care AG24 Aug
  • 6-KCurrent report (foreign private issuer)4 Aug
  • 6-KCurrent report (foreign private issuer)3 Aug
  • 6-KCurrent report (foreign private issuer)3 Aug
  • 6-KCurrent report (foreign private issuer)3 Aug
  • 6-KCurrent report (foreign private issuer)29 Jul
  • SC 13GFresenius Medical Care AG28 Jul
  • 11-KAnnual report (employee stock purchase/savings/profit sharing plans)29 Jun
  • 6-KCurrent report (foreign private issuer)28 May
  • SDSD28 May
  • 6-KCurrent report (foreign private issuer)26 May
  • 6-KCurrent report (foreign private issuer)5 May
  • 6-KCurrent report (foreign private issuer)5 May

News

  • Dialysis Giants DaVita and Fresenius Blocking Competition In Washington, Lawsuit Accuses12 Nov
  • What Fresenius Medical Care AG & Co. KGaA (FMS) Said on Its Q3 Earnings Call4 Nov
  • Fresenius Medical Care AG (FMS) Q3 2026 Earnings Call Transcript3 Nov
  • Fresenius Medical Care reports third quarter 2026 performance partially offsetting headwinds and narrowing full year outlook3 Nov
  • Fresenius Medical cuts top end of 2026 profit outlook3 Nov
  • FMS Launches multiFiltratePRO System for U.S. Patients With Acute AKI23 Oct
  • Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™21 Oct
  • Fly Alliance to Replace Entire Flight Management System with flyExclusive's AI-Powered Contrails FMS21 Oct
  • Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 202619 Oct
  • Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now7 Oct
  • Fresenius Medical Care Reshapes China Portfolio for Long-Term Growth29 Sep
  • Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Has Consensus Price Target of $23.57 According to Brokerages28 Sep
  • Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership25 Sep
  • Tidal Investments LLC Buys 48,885 Shares of Fresenius Medical Care AG & Co. KGaA $FMS17 Sep
  • Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?3 Sep
  • Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now3 Sep
  • Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Share Price Passes Above 200 Day Moving Average – Time to Sell?21 Aug
  • 3 Cheap International Stocks to Buy19 Aug

Mentions in Filings

  • … 2025 and Circuit Clinical Solutions, Inc. since July 2016. From January 2004 to December 2009, Mr. Wahlström served as co-CEO of Fresenius Medical Care North America and a member of the management board at <strong>Fresenius Medical Care AG & Co. KGAA</strong>. From November 2002 to December 2009, he served as President and CEO of Fresenius Medical Services, which operated more than 1,700 dialysis clinics in the U.S. Prior to joining Fresenius Medical Care in 200 …
    Coherus Oncology, Inc.Fresenius Medical Care AG American Depositary Receipt·DEF 14A - Definitive proxy statement·Q2 26·20 Apr
  • … 2025 and Circuit Clinical Solutions, Inc. since July 2016. From January 2004 to December 2009, Mr. Wahlström served as co-CEO of Fresenius Medical Care North America and a member of the management board at <strong>Fresenius Medical Care AG & Co. KGAA</strong>. From November 2002 to December 2009, he served as President and CEO of Fresenius Medical Services, which operated more than 1,700 dialysis clinics in the U.S. Prior to joining Fresenius Medical Care in 200 …
    Coherus Oncology, Inc.Fresenius Medical Care AG American Depositary Receipt·PRE 14A - Preliminary proxy statement·Q2 26·9 Apr
  • … 2025, and Circuit Clinical Solutions, Inc. since July 2016. From January 2004 to December 2009, Mr. Wahlström served as co-CEO of Fresenius Medical Care North America and a member of the Management Board at <strong>Fresenius Medical Care AG & Co. KGaA</strong>. From November 2002 to December 2009, Mr. Wahlström served as President and Chief Executive Officer of Fresenius Medical Services. Prior to that, Mr. Wahlström held various positions at Gambro AB from Janua …
    TriSalus Life Sciences, Inc.Fresenius Medical Care AG American Depositary Receipt·DEF 14A - Definitive proxy statement·Q4 25·30 Mar
  • There are a number of dialysis machine manufacturers and dialysis service providers in the United States, Europe and Asia. Notable competitors in the United States include <strong>Fresenius Medical Care AG & Co. KGaA</strong> (Fresenius); DaVita, Inc. (DaVita), a dialysis service provider; Mozarc Medical, a dialysis products joint venture formed by DaVita and Medtronic plc (Medtronic); and B. Braun Medical Inc. (B. Braun). Vantive, formerly the Baxter kidney care …
    Outset Medical, Inc.Fresenius Medical Care AG American Depositary Receipt·10-K - Annual report FY 2025·FY25·13 Feb
  • In addition, Mr. Wahlström has served as the Chairman of the board of directors of Triomed AB since October 2016, as the lead independent director of Coherus Biosciences, Inc., a public biotech company, since January 2012, as Chairman of Caduceus Medical Holdings, Inc. since August 2010 and as Chief Executive Officer and Chairman of Leonard Capital since July 2010. Mr. Wahlström has served on the boards of directors of Alteco Medical AB since Oct …
    TriSalus Life Sciences, Inc.Fresenius Medical Care AG American Depositary Receipt·S-4/A - Registration statement (business combination, amendment)·Q3 25·11 Jul 2025
  • … listed companies, have been elected to the Supervisory Board by the shareholders. They share extensive accounting and auditing expertise, as does Laurence Rosen (former CFO of the Company and former CFO of <strong>Fresenius Medical Care AG & Co. KGaA</strong>). Both Supervisory Board members' accounting and auditing expertise also extends to sustainability reporting and auditing. The contract with the accounting auditor stipulates that if any potential circumst …
    ドイツポスト・アーゲーFresenius Medical Care AG American Depositary Receipt·Annual Report - Annual Securities Report (2024.01.01-2024.12.31)·30 Jun 25·29 Jun 2025

Key Stats

Trading

Px/Chg 1D$22.35 / +0.43%
Avg Volume679.08K
Beta0.37
Mkt Cap12.00B
FD Mkt Cap12.41B

Float

Shrs Out/Float537.13M / 532.21M
Short Float0.01%
Days to Cover5.05
Stock Repurchased$347.33M

Current Valuation

EV22.76B
EV/EBITDA6.65
EV/Sales1.18
P/B0.91
P/S0.62
FCF Yield0.31%
ROE0.89%
ROA0.37%
Current Ratio1.20

Dividend

Cash$0.87
Yield4.03%
Yield (TTM)4.03%

Estimates

P/E12.71
Est P/E0.00
Est EPS0.59
Est PEG0.00

Valuation

Metric5Yr AvgJun '23Mar '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings45.9837.5022.6828.0039.60102.12
Price / Sales1.561.300.580.782.552.60
Price / Book Value1.101.810.831.030.910.91
Price / Free Cash Flow76.2317.505.828.9322.96325.96
ENTERPRISE VALUE METRICS
Enterprise Value26,566.438,652.923,198.526,077.622,147.622,755.3
Enterprise Value / Sales2.771.991.191.354.374.93
Enterprise Value / EBITDA15.8111.317.238.1322.5829.79
Enterprise Value / EBIT34.0624.4715.9117.8136.4675.65

Financials

Full Financials
Millions EUR5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue2.7%17,618.719,398.019,453.619,335.919,627.6
Gross Income1.3%4,773.04,893.74,925.04,756.75,028.9
EBITDA-1.1%3,549.13,417.83,209.63,206.23,397.1
EBIT-37.6%1,925.51,579.41,457.71,464.01,896.6
Net Income23.3%969.3673.4499.0537.9978.4
EPS (Diluted)19.3%0.830.570.850.921.68
BALANCE SHEET
Cash & ST Inv-64.4%1,640.81,461.61,557.91,343.31,599.0
Total Assets-2.5%34,366.635,754.133,929.833,566.631,002.0
Total Liabilities-4.8%20,387.520,304.919,103.317,798.116,719.0
Total Shareholder Equity3%12,698.813,989.513,620.314,576.614,283.0
CASH FLOW
Net Operating Cash Flow85%2,489.52,167.42,628.82,386.12,575.2
Cap Ex72%-854.4-724.0-684.6-699.4-879.2
Free Cash Flow91.7%1,635.11,443.41,944.21,686.81,695.9

Enterprise Value Bridge

Millions EUR13 Nov '26
Price (As of 13 Nov '26)22.13
Basic Shares537.13
Market Cap11,886.7
Diluted Shares524.00
Fully Diluted Shares Outstanding524.00
Fully Diluted Market Cap11,596.1
+Consolidated Debt10,886.5
−In-the-Money Convertible Debt—
+Capital Leases3,349.5
+Operating Leases—
−Cash & Equivalents-1,099.1
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest964.8
+Pension Liabilities—
Enterprise Value22,638.9

Segment data

Revenue

by Products and services

  • Health Care Services75%
  • Health Care Products25%

Revenue

by Geography

  • United States97%
  • Germany3%

Related companies

Davita Inc.

DVA US

Park Dental Partners, Inc.

PARK US

Cryo Cell International Inc

CCEL US

Pacific Health Care Organization Inc

PFHO US

Mangoceuticals, Inc.

MGRX US

BioRestorative Therapies, Inc.

BRTX US

Telemynd, Inc.

PSYC US

NewGenIvf Group Ltd

NIVF US

Ontrak, Inc.

OTRKQ US

AnTix Holdings, Inc.

IMTH US

American Renal Associates Holdings, Inc.

ARA B1

P/E (TTM)
12.71
P/B (TTM)
0.91
Dividend Yield
4.03%
ROE (TTM)
0.89%
ROA (TTM)
0.37%
Operating Margin
8.14%
Beta
0.37

Dividends

Last Dividend
$0.87
Last Yield
0.04%

Summary

Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.

Website
www.freseniusmedicalcare.com
Location
Bad Homburg, 2M, DE
Phone49 6172 608 2522
Employees108,165
CEOHelen Giza
SectorHealthcare
IndustryMedical - Care Facilities
IPO DateSep 17, 1996

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(572)

Expand
  • SC 13D/AFresenius Medical Care AG03:26PM
  • 6-KCurrent report (foreign private issuer)9 Nov
  • 6-KCurrent report (foreign private issuer)3 Nov
  • 6-KCurrent report (foreign private issuer)3 Nov
  • 6-KCurrent report (foreign private issuer)7 Oct
  • 6-KCurrent report (foreign private issuer)25 Sep
  • 6-KCurrent report (foreign private issuer)27 Aug
  • SC 13D/AFresenius Medical Care AG24 Aug
  • 6-KCurrent report (foreign private issuer)4 Aug
  • 6-KCurrent report (foreign private issuer)3 Aug
  • 6-KCurrent report (foreign private issuer)3 Aug
  • 6-KCurrent report (foreign private issuer)3 Aug
  • 6-KCurrent report (foreign private issuer)29 Jul
  • SC 13GFresenius Medical Care AG28 Jul
  • 11-KAnnual report (employee stock purchase/savings/profit sharing plans)29 Jun
  • 6-KCurrent report (foreign private issuer)28 May
  • SDSD28 May
  • 6-KCurrent report (foreign private issuer)26 May
  • 6-KCurrent report (foreign private issuer)5 May
  • 6-KCurrent report (foreign private issuer)5 May

News

  • Dialysis Giants DaVita and Fresenius Blocking Competition In Washington, Lawsuit Accuses12 Nov
  • What Fresenius Medical Care AG & Co. KGaA (FMS) Said on Its Q3 Earnings Call4 Nov
  • Fresenius Medical Care AG (FMS) Q3 2026 Earnings Call Transcript3 Nov
  • Fresenius Medical Care reports third quarter 2026 performance partially offsetting headwinds and narrowing full year outlook3 Nov
  • Fresenius Medical cuts top end of 2026 profit outlook3 Nov
  • FMS Launches multiFiltratePRO System for U.S. Patients With Acute AKI23 Oct
  • Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™21 Oct
  • Fly Alliance to Replace Entire Flight Management System with flyExclusive's AI-Powered Contrails FMS21 Oct
  • Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 202619 Oct
  • Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now7 Oct
  • Fresenius Medical Care Reshapes China Portfolio for Long-Term Growth29 Sep
  • Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Has Consensus Price Target of $23.57 According to Brokerages28 Sep
  • Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership25 Sep
  • Tidal Investments LLC Buys 48,885 Shares of Fresenius Medical Care AG & Co. KGaA $FMS17 Sep
  • Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?3 Sep
  • Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now3 Sep
  • Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Share Price Passes Above 200 Day Moving Average – Time to Sell?21 Aug
  • 3 Cheap International Stocks to Buy19 Aug

Mentions in Filings

  • … 2025 and Circuit Clinical Solutions, Inc. since July 2016. From January 2004 to December 2009, Mr. Wahlström served as co-CEO of Fresenius Medical Care North America and a member of the management board at <strong>Fresenius Medical Care AG & Co. KGAA</strong>. From November 2002 to December 2009, he served as President and CEO of Fresenius Medical Services, which operated more than 1,700 dialysis clinics in the U.S. Prior to joining Fresenius Medical Care in 200 …
    Coherus Oncology, Inc.Fresenius Medical Care AG American Depositary Receipt·DEF 14A - Definitive proxy statement·Q2 26·20 Apr
  • … 2025 and Circuit Clinical Solutions, Inc. since July 2016. From January 2004 to December 2009, Mr. Wahlström served as co-CEO of Fresenius Medical Care North America and a member of the management board at <strong>Fresenius Medical Care AG & Co. KGAA</strong>. From November 2002 to December 2009, he served as President and CEO of Fresenius Medical Services, which operated more than 1,700 dialysis clinics in the U.S. Prior to joining Fresenius Medical Care in 200 …
    Coherus Oncology, Inc.Fresenius Medical Care AG American Depositary Receipt·PRE 14A - Preliminary proxy statement·Q2 26·9 Apr
  • … 2025, and Circuit Clinical Solutions, Inc. since July 2016. From January 2004 to December 2009, Mr. Wahlström served as co-CEO of Fresenius Medical Care North America and a member of the Management Board at <strong>Fresenius Medical Care AG & Co. KGaA</strong>. From November 2002 to December 2009, Mr. Wahlström served as President and Chief Executive Officer of Fresenius Medical Services. Prior to that, Mr. Wahlström held various positions at Gambro AB from Janua …
    TriSalus Life Sciences, Inc.Fresenius Medical Care AG American Depositary Receipt·DEF 14A - Definitive proxy statement·Q4 25·30 Mar
  • There are a number of dialysis machine manufacturers and dialysis service providers in the United States, Europe and Asia. Notable competitors in the United States include <strong>Fresenius Medical Care AG & Co. KGaA</strong> (Fresenius); DaVita, Inc. (DaVita), a dialysis service provider; Mozarc Medical, a dialysis products joint venture formed by DaVita and Medtronic plc (Medtronic); and B. Braun Medical Inc. (B. Braun). Vantive, formerly the Baxter kidney care …
    Outset Medical, Inc.Fresenius Medical Care AG American Depositary Receipt·10-K - Annual report FY 2025·FY25·13 Feb
  • In addition, Mr. Wahlström has served as the Chairman of the board of directors of Triomed AB since October 2016, as the lead independent director of Coherus Biosciences, Inc., a public biotech company, since January 2012, as Chairman of Caduceus Medical Holdings, Inc. since August 2010 and as Chief Executive Officer and Chairman of Leonard Capital since July 2010. Mr. Wahlström has served on the boards of directors of Alteco Medical AB since Oct …
    TriSalus Life Sciences, Inc.Fresenius Medical Care AG American Depositary Receipt·S-4/A - Registration statement (business combination, amendment)·Q3 25·11 Jul 2025
  • … listed companies, have been elected to the Supervisory Board by the shareholders. They share extensive accounting and auditing expertise, as does Laurence Rosen (former CFO of the Company and former CFO of <strong>Fresenius Medical Care AG & Co. KGaA</strong>). Both Supervisory Board members' accounting and auditing expertise also extends to sustainability reporting and auditing. The contract with the accounting auditor stipulates that if any potential circumst …
    ドイツポスト・アーゲーFresenius Medical Care AG American Depositary Receipt·Annual Report - Annual Securities Report (2024.01.01-2024.12.31)·30 Jun 25·29 Jun 2025

Key Stats

Trading

Px/Chg 1D$22.35 / +0.43%
Avg Volume679.08K
Beta0.37
Mkt Cap12.00B
FD Mkt Cap12.41B

Float

Shrs Out/Float537.13M / 532.21M
Short Float0.01%
Days to Cover5.05
Stock Repurchased$347.33M

Current Valuation

EV22.76B
EV/EBITDA6.65
EV/Sales1.18
P/B0.91
P/S0.62
FCF Yield0.31%
ROE0.89%
ROA0.37%
Current Ratio1.20

Dividend

Cash$0.87
Yield4.03%
Yield (TTM)4.03%

Estimates

P/E12.71
Est P/E0.00
Est EPS0.59
Est PEG0.00

Valuation

Metric5Yr AvgJun '23Mar '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings45.9837.5022.6828.0039.60102.12
Price / Sales1.561.300.580.782.552.60
Price / Book Value1.101.810.831.030.910.91
Price / Free Cash Flow76.2317.505.828.9322.96325.96
ENTERPRISE VALUE METRICS
Enterprise Value26,566.438,652.923,198.526,077.622,147.622,755.3
Enterprise Value / Sales2.771.991.191.354.374.93
Enterprise Value / EBITDA15.8111.317.238.1322.5829.79
Enterprise Value / EBIT34.0624.4715.9117.8136.4675.65

Financials

Full Financials
Millions EUR5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue2.7%17,618.719,398.019,453.619,335.919,627.6
Gross Income1.3%4,773.04,893.74,925.04,756.75,028.9
EBITDA-1.1%3,549.13,417.83,209.63,206.23,397.1
EBIT-37.6%1,925.51,579.41,457.71,464.01,896.6
Net Income23.3%969.3673.4499.0537.9978.4
EPS (Diluted)19.3%0.830.570.850.921.68
BALANCE SHEET
Cash & ST Inv-64.4%1,640.81,461.61,557.91,343.31,599.0
Total Assets-2.5%34,366.635,754.133,929.833,566.631,002.0
Total Liabilities-4.8%20,387.520,304.919,103.317,798.116,719.0
Total Shareholder Equity3%12,698.813,989.513,620.314,576.614,283.0
CASH FLOW
Net Operating Cash Flow85%2,489.52,167.42,628.82,386.12,575.2
Cap Ex72%-854.4-724.0-684.6-699.4-879.2
Free Cash Flow91.7%1,635.11,443.41,944.21,686.81,695.9

Enterprise Value Bridge

Millions EUR13 Nov '26
Price (As of 13 Nov '26)22.13
Basic Shares537.13
Market Cap11,886.7
Diluted Shares524.00
Fully Diluted Shares Outstanding524.00
Fully Diluted Market Cap11,596.1
+Consolidated Debt10,886.5
−In-the-Money Convertible Debt—
+Capital Leases3,349.5
+Operating Leases—
−Cash & Equivalents-1,099.1
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest964.8
+Pension Liabilities—
Enterprise Value22,638.9

Segment data

Revenue

by Products and services

  • Health Care Services75%
  • Health Care Products25%

Revenue

by Geography

  • United States97%
  • Germany3%

Related companies

Davita Inc.

DVA US

Park Dental Partners, Inc.

PARK US

Cryo Cell International Inc

CCEL US

Pacific Health Care Organization Inc

PFHO US

Mangoceuticals, Inc.

MGRX US

BioRestorative Therapies, Inc.

BRTX US

Telemynd, Inc.

PSYC US

NewGenIvf Group Ltd

NIVF US

Ontrak, Inc.

OTRKQ US

AnTix Holdings, Inc.

IMTH US

American Renal Associates Holdings, Inc.

ARA B1